In summary, these results demonstrate that, as the EGFR inhibitors, Erlotinib and Nimotuzumab, prevent Foxq1 from promoting VM formation, and NPC growth and metastasis. Here, FOXQ1 is linked to nasopharyngeal carcinoma.